CalciMedica, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CalciMedica, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.56M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($13.70M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($34.36M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($7.82M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($35.82M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($27.53M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($37.04M) | Mar 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.12M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($24.20M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($38.08M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.19M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($35.95M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($29.83M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($37.50M) | Mar 5, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.23M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $14.48M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $15.86M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.35M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $18.90M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $20.96M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $30.58M | Mar 5, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.18M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($21.15M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($25.73M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($11.76M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($31.50M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($32.06M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($31.22M) | Mar 5, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.0K | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $8.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $78.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $488.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.02M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $605.0K | Mar 5, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.59M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $19.79M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $12.19M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.35M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $69.09M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $101.79M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $40.66M | Mar 5, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.23M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $5.38M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $4.03M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $12.58M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.07M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $7.01M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $12.25M | Mar 5, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.64M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $14.41M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $8.16M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($71.30M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($63.99M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $94.79M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | ($102.95M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | ($66.79M) | Mar 5, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($189.33M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($159.76M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($146.06M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($111.71M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($169.19M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($133.37M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($105.84M) | Mar 5, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.52M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $7.94M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $5.53M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.33M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $13.36M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $33.42M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $15.87M | Mar 5, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (7) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (111) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (7) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (111) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.44M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 13.48M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 5.75M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 84,165 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 21.36M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 20.98M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 1.37M | Mar 5, 2021 |